Loading
A phase 2 trial of CVM-1118 in neuroendocrine tumours and pancreatic ductal adenocarcinoma, run by TaiRx, Inc., active and no longer recruiting.
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors is a phase 2 interventional study registered as NCT03600233 by TaiRx, Inc., with 34 participants enrolled, started 2018-12-15 and due to reach its primary completion in 2024-09-30. Interventions recorded: CVM-1118.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/